No Data
No Data
Company profit warning: Biosyentech (02315) is expected to have a maximum mid-term loss of 5.47 million RMB, a decrease in losses of up to 76.4% year-on-year.
As of June 30, 2024, the six-month period, Baiostar (02315) announced an expected loss of approximately 4.47 million to 5.47 million yuan (RMB), a decrease of approximately 1.351 million to 1.451 million yuan compared to the same period of the previous year, a year-on-year decrease of approximately 71.2% to 76.4%. The Group's estimated revenue for the first half of the year is expected to be approximately 0.406 billion to 0.416 billion yuan, an increase of approximately 7.87 million to 8.87 million yuan compared to the same period of the previous year, a year-on-year increase of approximately 24.1% to 27.1%. The Group's estimated R&D expenses in the first half of the year.
Biosoter-B (02315.HK) is expected to have a year-on-year revenue growth of 24.1%-27.1% in the first half of the year, and the losses will be significantly reduced.
On August 7th, Grong Hui announced its interim report ending on June 30, 2024. In the first half of 2024, the expected revenue is about RMB 0.4055 billion to RMB 0.4155 billion, a year-on-year increase of about 24.1% to 27.1%. The expected loss is about RMB 44.7 million to RMB 54.7 million, a year-on-year decrease of about 71.2% to 76.4%. The Group's expected R&D expense for the first half of 2024 is about RMB 0.1567 billion to RMB 0.1667 billion, a year-on-year decrease of about 32.8% to 36%.
Express News | IDEAYA Biosciences Inc - Total Potential Payments Under Agreement Equal $406.5 Million
Express News | Biocytogen Announces Option and License Agreement With IDEAYA Biosciences for Potential First-in-Class B7H3/Ptk7 Topo-I-Payload Bispecific ADC Program
Bio-Thera Solutions (02315.HK): has reached a selection and licensing agreement with IDEAYA for the B7H3/PTK7 topological isomerase inhibitor dual-specificity ADC project with the potential for the same innovation as similar products.
Biosat Biotechnology-B (02315.HK) has released an announcement that the company has reached a selection and authorization agreement with IDEAYA Biosciences (whose common stock is listed on Nasdaq Global Select Market under the stock codes "IDYA" and "IDEAY") today.
Bio-Thera signed a multi-target antibody collaboration agreement with SOTIO.
BeiGene (02315) announced that the company has reached a research collaboration and exclusive option and licensing agreement with SOTIO Biotech (SOTIO) today. According to the agreement, SOTIO is granted an option to license the use of multiple fully human bispecific antibodies generated from BeiGene's proprietary RenLite platform, and SOTIO will use these antibodies for the development of next-generation antibody-drug conjugates (ADCs) targeting solid tumors. The agreement also includes an option for SOTIO to use BeiGene's proprietary ADC platform. According to the terms of the agreement, BeiGene has the
No Data
meowmeow66 : I dont think moomoo can order this IPO. you can ask customer service to double check.